glp-1 receptor agonist bcbs MCT2D MCT2D | 2023 Updates to

Side Effects: As a GLP-1 therapy, common side effects are typically gastrointestinal, including nausea, vomiting, and diarrhea.

Methods This is a cohort study combining several population-wide databases and covering a Spanish population of five million inhabitants, including all adults with obesity who initiated treatment with either GLP-1RA or SGLT-2i for type 2 diabetes from 2015 to 2021

Originally designed to manage type 2 diabetes (T2D), these drugs have rapidly expanded their therapeutic reach, offering significant benefits for ob

TIIDM is primarily found in middle-aged and elderly individuals

Thirteen state Medicaid programs are covering GLP-1 drugs for the treatment of obesity this year, down from 16 last year.

Recent Findings Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D